Stoke Therapeutics Inc (STOK) — Cash Flow-to-Debt Ratio
Stoke Therapeutics Inc (STOK) has a Cash Flow-to-Debt Ratio of -1.17x as of June 2026, meaning its operating cash flow of $-56.59 Million could theoretically repay -1% of its total liabilities ($48.42 Million) in one year. See financial flexibility index of Stoke Therapeutics Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Stoke Therapeutics Inc Cash Flow-to-Debt Ratio (2017–2025)
Historical debt coverage capacity for Stoke Therapeutics Inc across 9 annual periods. For the full cash flow conversion analysis, see Stoke Therapeutics Inc (STOK) cash conversion ratio.
Annual Cash Flow-to-Debt Ratio for Stoke Therapeutics Inc (2017–2025)
Year-by-year debt coverage analysis for Stoke Therapeutics Inc. Check STOK cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.69x | $45.59 Million | $65.98 Million | ▲ +133.8% |
| 2024 | -2.04x | $-86.85 Million | $42.53 Million | ▼ -73.2% |
| 2023 | -1.18x | $-81.07 Million | $68.78 Million | ▼ -163.4% |
| 2022 | -0.45x | $-31.87 Million | $71.22 Million | ▲ +85.9% |
| 2021 | -3.17x | $-66.91 Million | $21.09 Million | ▲ +11.0% |
| 2020 | -3.56x | $-42.22 Million | $11.85 Million | ▲ +50.4% |
| 2019 | -7.19x | $-31.05 Million | $4.32 Million | ▼ -61.9% |
| 2018 | -4.44x | $-10.96 Million | $2.47 Million | ▼ -207.5% |
| 2017 | -1.44x | $-5.38 Million | $3.73 Million | — |